A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myeloma

Lignende værker

• Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
  af: Zah, Eugenia, et al.
  Udgivet: (2020)
• Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
  af: Lin, Quande, et al.
  Udgivet: (2019)
• sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
  af: Katja Seipel, et al.
  Udgivet: (2022-03-01)
• BCMA CAR T-cell therapy arrives for multiple myeloma: a reality
  af: Cho, Shih-Feng, et al.
  Udgivet: (2018)
• Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
  af: Roex, Gils, et al.
  Udgivet: (2020)